Dr. Alison Campbell is Chief Scientific Officer of the Care Fertility Group, overseeing 19 IVF laboratories across the UK, Ireland, Spain, and the US. As a Consultant Embryologist and Fellow of the Royal College of Pathologists, Professor Campbell brings a wealth of expertise to the field of Embryology. Her contributions include a substantial body of published work, reflecting her commitment to reproductive medicine. Alison is a pioneering figure in the field of clinical embryology, having developed, implemented, and authored time-lapse algorithms for predicting ploidy and live births. Her team has also achieved significant advancements, creating an artificial intelligence tool named Caremaps-AI®. The groundbreaking tool, designed to support embryo selection, was awarded a National Technology Award in Healthcare 2023 and has earned a Royal College of Pathologists Achievement award. Alison actively shares her knowledge and experience, lecturing worldwide and participating on scientific advisory boards including the scientific and clinical advances advisory committee (SCAAC) for the UK’s regulator (HFEA). She is also part of the editorial boards for Human Reproduction and Reproductive BioMedicine Online.
Dr. Iain M. Dykes is a Senior Lecturer in molecular biology at Liverpool John Moores University, UK. He has over 25 years of research experience in the field of embryonic development undertaken at numerous institutions in the UK and US, including Oxford University, Great Ormond St Institute of Child Health and the University of California San Diego. He is particularly interested in the genetic control of development and has published extensively on subjects ranging from congenital disease to stem cells and epigenetics. His major contributions include the identification of two novel genes linked to congenital heart disease and the discovery of a novel regulator of haemoglobin switching. His current research is primarily focussed on diagnostics and therapeutics applications of molecular biology. He is investigating the use of extracellular vesicles for prenatal diagnosis of congenital heart disease as well as the development of a point-of-care sensor for micro RNA and the use of synthetic nanoparticles to deliver micro RNA based drugs to treat disease.
